Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read moreNew post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read moreNubilaria is providing it’s innovative ACTide EDC system free in support of a clinical study for COVID-19 related ARDS intensive
Read moreARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine
Read moreItalian IT and complex database consultancy Nubilaria is offering it’s cutting edge ACTide EDC web platform free of charge to
Read moreSuccess on the Innovation Index is important, especially now, at a time when innovation is needed more than ever. Many,
Read moreWith more than 100,000 confirmed novel coronavirus cases reported across 93 countries and 3400+ deaths, a coronavirus vaccine is needed
Read more